Adjuvant Chemoradiotherapy in Patients With Stage III or IV Radically Resected Gastric Cancer

Orditura, Michele; Vita, Ferdinando De; Muto, Paolo; Vitiello, Fabiana; Murino, Paola; Lieto, Eva; Vecchione, Loredana; Romano, Anna; Martinelli, Erika; Renda, Andrea; Ferraraccio, Francesca; Genio, A. Del; Ciardiello, Fortunato; Galizia, Gennaro

doi:10.1001/archsurg.2010.2

Cited by 18 publications

(15 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our series, toxicity was acceptable, with most adverse events being grade 1 or 2, and no treatmentrelated deaths being recorded. Dose reduction was required in 8 patients, and rates of grades 3 and 4 hematologic and nonhematologic toxicities were similar to those reported in other phase ii trials of preoperative crt (including oxaliplatin and 5fu-based chemotherapy) in esophageal or gej cancer [29][30][31][32] and also by our group in earlier work involving resected high-risk gastric cancer patients 13 . Those results are particularly interesting because our study used a higher radiotherapy dose than that reported in the German study (45 Gy vs. 30 Gy).…”

Section: Discussionsupporting

confidence: 80%

Effect of Preoperative Chemoradiotherapy on Outcome of Patients with Locally Advanced Esophagogastric Junction Adenocarcinoma—A Pilot Study

et al. 2014

View full text Add to dashboard Cite

examination of surgical specimens demonstrated a 10% complete response rate. The median and mean survival times were 26 and 36 months respectively (95% confidence interval: 14 to 37 months and 30 to 41 months respectively). On multivariate analysis, TNM staging and clinical response were demonstrated to be the only independent variables related to long-term survival. ConclusionsIn our experience, preoperative chemoradiotherapy with folfox4 is feasible in locally advanced gej adenocarcinoma, but shows mild efficacy, as suggested by the low rate of pathologic complete response.

show abstract

Section: Discussionsupporting

confidence: 80%

Effect of Preoperative Chemoradiotherapy on Outcome of Patients with Locally Advanced Esophagogastric Junction Adenocarcinoma—A Pilot Study

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Although multi-model treatment strategies including surgery, perioperative chemotherapy, radiotherapy and immunotherapy are used, the five-year survival rate for patients suffering from gastric cancer is still 25% or less [3-7]. Therefore, it is necessary to improve current therapeutic modalities and to explore new biological molecular markers for predicting the progression of gastric cancer and helping targeted therapy.…”

Section: Introductionmentioning

confidence: 99%

Serum B7-H4 expression is a significant prognostic indicator for patients with gastric cancer

Shi

et al. 2014

World J Surg Onc

View full text Add to dashboard Cite

BackgroundB7-H4 is a novel B7 ligand that plays an important role in the T cell-mediated immune response as a negative regulator. Previous studies have suggested the aberrant expression of membrane B7-H4 in tumor cells. The aim of this study is to determine the expression levels of preoperative soluble B7-H4 (sB7-H4) in circulation and to investigate the correlations between sB7-H4 levels and clinicopathological parameters as well as the survival rate of patients with gastric cancer.MethodsBlood specimens from 132 patients with gastric cancer and 63 healthy volunteers were analyzed by sandwich enzyme-linked immunosorbent assay.ResultsMedian concentrations of sB7-H4 in patients with gastric cancer were significantly higher than those in healthy volunteers (16.85 versus 10.46 ng/mL; P = 0.008). Median levels of sB7-H4 were significantly correlated with tumor size, lymph node metastasis, the depth of tumor invasion and tumor-node-metastasis classification (P = 0.002, P = 0.001, P = 0.041 and P <0.001, respectively), but not with sex, age, tumor location or histological subtype (all P >0.05). Additionally, the overall survival rate was significantly lower in patients with high sB7-H4 levels when compared with low sB7-H4 levels (50.0% versus 77.3%, χ2 = 10.78, P = 0.001). Moreover, multivariate analysis demonstrated that the risk of death was significantly higher in patients with high sB7-H4 levels than in those with low sB7-H4 levels (P = 0.039).ConclusionssB7-H4 is a valuable blood marker for predicting the progression and prognosis of patients with gastric cancer.

show abstract

“…Even after a curative resection alone or after chemotherapy, more than 50% of patients are likely to experience local regional recurrence (3,4). Despite the development of more diagnostic techniques and new treatment modalities, the five-year survival rate of gastric cancer has not significantly changed.…”

Section: Introductionmentioning

confidence: 99%

MicroRNA-27a inhibitors alone or in combination with perifosine suppress the growth of gastric cancer cells

Liu

Sun

Song

et al. 2012

Molecular Medicine Reports

View full text Add to dashboard Cite

Abstract. is an oncogene that contributes to drug resistance in various types of cancer. However, the involvement of miR-27a in gastric cancer has yet to be elucidated. Perifosine is an alkylphospholipid exhibiting antitumor activity as shown in both preclinical studies and clinical trials. The effects of perifosine on gastric cancer have yet to be determined. Therefore, this study was conducted to detect the role of miR-27a and perifosine in human gastric cancer. miR-27a was found to be expressed in human gastric cancer tissues and cell lines by quantitative reverse-transcription polymerase chain reaction (qRT-PCR). The correlation between miR-27a expression and clinicopathological characteristics of gastric cancer. We also explored the growth inhibitory effect of perifosine on human gastric cancer cells with or without co-targeting miR-27a by sulforhodamine B (SRB) assay. The results showed that miR-27a expression was significantly upregulated in gastric cancer tissues, compared with their non-tumor adjacent tissues. High expression levels of miR-27a were associated with poor tumor histological grade (P=0.037). MiR-27a inhibitors suppressed the growth of MGC-803 cells. Assay results showed that perifosine exerted its activity selectively on the AGS cell line and the growth inhibitory effect of perifosine was enhanced significantly in combination with miR-27a inhibitors in MGC-803 cells. In conclusion, our results demonstrated that miR-27a may be a therapeutic target and potential prognostic biological marker in gastric cancer. MiR-27a inhibitors alone or in combination with perifosine may be a novel therapeutic approach against gastric cancer.

show abstract

Adjuvant Chemoradiotherapy in Patients With Stage III or IV Radically Resected Gastric Cancer

Abstract: A multimodal approach with FOLFOX-4 and radiotherapy is feasible and effective for the treatment of patients with resected high-risk gastric cancer.

Cited by 18 publications

References 34 publications

Effect of Preoperative Chemoradiotherapy on Outcome of Patients with Locally Advanced Esophagogastric Junction Adenocarcinoma—A Pilot Study

Effect of Preoperative Chemoradiotherapy on Outcome of Patients with Locally Advanced Esophagogastric Junction Adenocarcinoma—A Pilot Study

Serum B7-H4 expression is a significant prognostic indicator for patients with gastric cancer

MicroRNA-27a inhibitors alone or in combination with perifosine suppress the growth of gastric cancer cells

Contact Info

Product

Resources

About